Ziyuglycoside I
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H112199

CAS#: 35286-58-9

Description: Ziyuglycoside I increases the synthesis of type I collagen in CCD-1064Sk human fibroblast cells and inhibits the proliferation of MDA-MB-231 breast cancer cells.

Chemical Structure

img
Ziyuglycoside I
CAS# 35286-58-9
Instruction

Theoretical Analysis

Hodoodo Cat#: H112199
Name: Ziyuglycoside I
CAS#: 35286-58-9
Chemical Formula: C41H66O13
Exact Mass: 766.45
Molecular Weight: 766.970
Elemental Analysis: C, 64.21; H, 8.67; O, 27.12

Price and Availability

Size Price Availability Quantity
1mg USD 260 2 Weeks
5mg USD 660 2 Weeks
10mg USD 1000 2 Weeks
25mg USD 1710 2 Weeks
Bulk inquiry

Synonym: Gouguside 7, Ziyuglycoside I

IUPAC/Chemical Name: (2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl (1R,2R,4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-(((2S,3R,4S,5S)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2H)-carboxylate

InChi Key: WCHBFWOEFOZHMK-MLHVESHNSA-N

InChi Code: InChI=1S/C41H66O13/c1-20-10-15-41(35(49)54-34-31(48)29(46)28(45)23(18-42)52-34)17-16-38(5)21(32(41)40(20,7)50)8-9-25-37(4)13-12-26(36(2,3)24(37)11-14-39(25,38)6)53-33-30(47)27(44)22(43)19-51-33/h8,20,22-34,42-48,50H,9-19H2,1-7H3/t20-,22+,23-,24+,25-,26+,27+,28-,29+,30-,31-,32-,33+,34+,37+,38-,39-,40-,41+/m1/s1

SMILES Code: OC[C@@H](O[C@H]1OC([C@@]23[C@]([H])(C4=CC[C@]5([H])[C@]6(C)[C@@]([H])(CC[C@]5([C@]4(C)CC3)C)C([C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)CC6)(C)C)[C@]([C@H](C)CC2)(C)O)=O)[C@@H](O)[C@H](O)[C@H]1O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMF 10.0 13.04
DMSO 5.0 6.52
Ethanol 5.0 6.52

Preparing Stock Solutions

The following data is based on the product molecular weight 766.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Park KR, Lee JY, Cho M, Yun HM. Ziyuglycoside I Upregulates RUNX2 through ERK1/2 in Promoting Osteoblast Differentiation and Bone Mineralization. Am J Chin Med. 2021;49(4):883-900. doi: 10.1142/S0192415X21500427. Epub 2021 Apr 7. PMID: 33829967.


2: Song T, Wang H, Liu Y, Cai R, Yang D, Xiong Y. TPGS-Modified Long-Circulating Liposomes Loading Ziyuglycoside I for Enhanced Therapy of Myelosuppression. Int J Nanomedicine. 2021 Sep 14;16:6281-6295. doi: 10.2147/IJN.S326629. PMID: 34548791; PMCID: PMC8449650.


3: Zhu X, Wang K, Zhang K, Zhang T, Yin Y, Xu F. Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis. Int J Mol Sci. 2016 Nov 22;17(11):1903. doi: 10.3390/ijms17111903. PMID: 27879682; PMCID: PMC5133901.


4: Zhu X, Wang K, Yao Y, Zhang K, Zhou F, Zhu L. Triggering p53 activation is essential in ziyuglycoside I-induced human retinoblastoma WERI-Rb-1 cell apoptosis. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22001. Epub 2017 Sep 28. PMID: 28960612.


5: Sun H, Wang M, Su T, Guo P, Tai Y, Cheng H, Zhu Z, Jiang C, Yan S, Wei W, Zhang L, Wang Q. Ziyuglycoside I attenuates collagen-induced arthritis through inhibiting plasma cell expansion. J Ethnopharmacol. 2022 Aug 10;294:115348. doi: 10.1016/j.jep.2022.115348. Epub 2022 May 6. PMID: 35533910.


6: Kim YH, Chung CB, Kim JG, Ko KI, Park SH, Kim JH, Eom SY, Kim YS, Hwang YI, Kim KH. Anti-wrinkle activity of ziyuglycoside I isolated from a Sanguisorba officinalis root extract and its application as a cosmeceutical ingredient. Biosci Biotechnol Biochem. 2008 Feb;72(2):303-11. doi: 10.1271/bbb.70268. Epub 2008 Feb 7. PMID: 18256460.


7: Li ZF, Zhou MY, Tan T, Zhong CC, Wang Q, Pan LL, Luo YY, Yang SL, Feng YL, Ouyang H. A Sample and Sensitive HPLC-MS/MS Method for Simultaneous Determination of Ziyuglycoside I and Its Metabolite Ziyuglycoside II in Rat Pharmacokinetics. Molecules. 2018 Feb 28;23(3):543. doi: 10.3390/molecules23030543. PMID: 29495641; PMCID: PMC6017276.


8: Zhu LJ, Chen L, Bai CF, Wu AG, Liang SC, Huang FH, Cao SS, Yang L, Zou WJ, Wu JM. A rapid and sensitive UHPLC-MS/MS method for the determination of ziyuglycoside I and its application in a preliminary pharmacokinetic study in healthy and leukopenic rats. Biomed Pharmacother. 2020 Mar;123:109756. doi: 10.1016/j.biopha.2019.109756. Epub 2019 Dec 25. PMID: 31864212.


9: Ye W, Fu H, Xie L, Zhou L, Rao T, Wang Q, Shao Y, Xiao J, Kang D, Wang G, Liang Y. Development and validation of a quantification method for ziyuglycoside I and II in rat plasma: Application to their pharmacokinetic studies. J Sep Sci. 2015 Jul;38(13):2340-7. doi: 10.1002/jssc.201500102. Epub 2015 May 15. PMID: 25885584.


10: Xiong Y, Zou Y, Chen L, Xu Y, Wang S. Development and In Vivo Evaluation of Ziyuglycoside I-Loaded Self-Microemulsifying Formulation for Activity of Increasing Leukocyte. AAPS PharmSciTech. 2019 Feb 5;20(3):101. doi: 10.1208/s12249-019-1313-3. PMID: 30721444; PMCID: PMC6373417.


11: Wang G, Fu H, Ye W, Zheng X, Xiao J, Kang D, Rao T, Shao Y, Xie L, Liang Y. Comprehensive characterization of the in vitro and in vivo metabolites of ziyuglycoside I in rat microsome, intestinal flora, excretion specimen and fresh tissues based on LC-Q-TOF/MS. J Pharm Biomed Anal. 2016 Sep 5;128:191-200. doi: 10.1016/j.jpba.2016.05.032. Epub 2016 May 20. PMID: 27268222.


12: Yun MY, Bae EY, Lee SW, Yim SH, Ly SY, Choi HJ. Anti-photoaging effect of skin cream manufactured with ziyuglycoside I isolated from Sanguisorba officinalis on ultraviolet B-induced hairless mice. Biosci Biotechnol Biochem. 2019 Jul;83(7):1197-1204. doi: 10.1080/09168451.2019.1607247. Epub 2019 Apr 19. PMID: 30999820.